论文部分内容阅读
目的:探究索利那新联合行为疗法在对托特罗定治疗无效的女性膀胱过度活动症患者进行治疗的安全性与临床价值。方法:随机在我院2014年1月至2014年12月收治的经托特罗定治疗无效的20例患者,对其改用索利那新,并配合行为疗法,观察患者的治疗效果并对患者接受治疗期间的不良反应发生情况进行分析。结果:患者改用新的治疗方法后,其治疗前后的症状及尿流动力指标有差异变化(P<0.05)。结论:使用索利那新联合行为法治疗女性膀胱过度活动症,不仅效果显著,并且不良反应的发生情况也较少,可以临床大量应用。
Objective: To explore the safety and clinical value of solifenacin combined behavioral therapy in the treatment of female patients with overactive bladder who are refractory to tolterodine treatment. Methods: Totally 20 patients who were treated with tolterodine randomly from January 2014 to December 2014 in our hospital were switched to solifenacin and treated with behavioral therapy to observe the effect of the treatment. Analysis of the occurrence of adverse reactions during treatment of patients. Results: After the patients switched to the new treatment method, their symptoms and urodynamic indexes changed before and after treatment (P <0.05). Conclusion: The treatment of female overactive bladder with solifenacin combined behavior is not only effective, but also has fewer adverse reactions and can be used clinically.